Recent

% | $
Quotes you view appear here for quick access.

SAVIENT PHARM INC Message Board

  • rodgers.david@rocketmail.com rodgers.david Feb 11, 2013 3:18 PM Flag

    seeking alpha article-

    primed and ready to go long...[not a pumper ,investor in stock not options or day trader]

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Thx david for bringing out attn to today's SVNT article from SA! Here it is. Nice SA is giving us a much needed no doubt positive spin...

      "(1) Savient Pharmaceuticals (SVNT) is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients who do not respond to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP"). Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted US and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns US and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA. Savient also supplies Oxandrin® (oxandrolone tablets, USP) CIII in the US. SVNT fell 10% last week finishing off Friday at $0.94 per share. There was no fundamental news causing the sell-off, making the discount a potential opportunity to go long pending further investigation. It has a short ratio of 14.3 and short interest of 20.1 million shares."

 
SVNTQ
0.00190.0000(0.00%)May 30 3:56 PMEDT